Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer

被引:8
|
作者
Wang, Yunzhen [1 ]
Huang, Sha [1 ]
Feng, Xiangwei [1 ]
Xu, Wangjue [2 ]
Luo, Raojun [1 ]
Zhu, Ziyi [1 ]
Zeng, Qingxin [1 ]
He, Zhengfu [1 ]
机构
[1] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Thorac Surg, Sch Med, Hangzhou, Peoples R China
[2] Longyou Cty Peoples Hosp, Dept Thorac Surg, Longyou, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
基金
中国国家自然科学基金;
关键词
non-small cell lung cancer; neoadjuvant immunotherapy; chemo-immunotherapy; efficacy prediction; biomarkers; IMMUNE CHECKPOINT INHIBITORS; PLATINUM-BASED CHEMOTHERAPY; TUMOR MUTATIONAL BURDEN; LYMPHOCYTE RATIO NLR; PD-L1; EXPRESSION; NSCLC-PATIENTS; FREE SURVIVAL; PEMBROLIZUMAB; OUTCOMES; MULTICENTER;
D O I
10.3389/fonc.2023.1145128
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The use of immune checkpoint inhibitors (ICIs) has become mainstream in the treatment of non-small cell lung cancer (NSCLC). The idea of harnessing the immune system to fight cancer is fast developing. Neoadjuvant treatment in NSCLC is undergoing unprecedented change. Chemo-immunotherapy combinations not only seem to achieve population-wide treating coverage irrespective of PD-L1 expression but also enable achieving a pathological complete response (pCR). Despite these recent advancements in neoadjuvant chemo-immunotherapy, not all patients respond favorably to treatment with ICIs plus chemo and may even suffer from severe immune-related adverse effects (irAEs). Similar to selection for target therapy, identifying patients most likely to benefit from chemo-immunotherapy may be valuable. Recently, several prognostic and predictive factors associated with the efficacy of neoadjuvant immunotherapy in NSCLC, such as tumor-intrinsic biomarkers, tumor microenvironment biomarkers, liquid biopsies, microbiota, metabolic profiles, and clinical characteristics, have been described. However, a specific and sensitive biomarker remains to be identified. Recently, the construction of prediction models for ICI therapy using novel tools, such as multi-omics factors, proteomic tests, host immune classifiers, and machine learning algorithms, has gained attention. In this review, we provide a comprehensive overview of the different positive prognostic and predictive factors in treating preoperative patients with ICIs, highlight the recent advances made in the efficacy prediction of neoadjuvant immunotherapy, and provide an outlook for joint predictors.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer
    Sanber, Khaled
    Rosner, Samuel
    Forde, Patrick M.
    Marrone, Kristen A.
    BIODRUGS, 2023, 37 (06) : 775 - 791
  • [2] Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer
    Khaled Sanber
    Samuel Rosner
    Patrick M. Forde
    Kristen A. Marrone
    BioDrugs, 2023, 37 : 775 - 791
  • [3] The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer
    Guven, Deniz Can
    Sahin, Taha Koray
    Kilickap, Saadettin
    CANCERS, 2024, 16 (01)
  • [4] Advances in Immunotherapy for Non-Small Cell Lung Cancer
    Reckamp, Karen L.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (12) : 847 - 853
  • [5] Neoadjuvant immunotherapy for resectable non-small cell lung cancer
    Xie, Hui
    Shi, Xuejun
    Wang, Guangshun
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (06): : 2521 - 2536
  • [6] Neoadjuvant Immunotherapy for Patients with non-small cell Lung Cancer
    Luecke, E.
    Ganzert, C.
    Waesche, A.
    Walles, T.
    Schreiber, J.
    PNEUMOLOGIE, 2020, 74 : S74 - S75
  • [7] Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
    Lochrin, Sarah E.
    Forde, Patrick M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (08) : 415 - 423
  • [8] Neoadjuvant immunotherapy with resectable non-small cell lung cancer: recent advances and future challenges
    Ren, Sijia
    Wang, Chunguo
    Shen, Jianfei
    Zhu, Chengchu
    JOURNAL OF THORACIC DISEASE, 2020, 12 (04) : 1615 - 1620
  • [9] New advances in immunotherapy for non-small cell lung cancer
    Qin, Haifeng
    Wang, Fang
    Liu, Hui
    Zeng, Zhen
    Wang, Shasha
    Pan, Xin
    Gao, Hongjun
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2018, 10 (08): : 2234 - 2245
  • [10] Advances in the Treatment of Non-Small Cell Lung Cancer: Immunotherapy
    Patel, Shetal A.
    Weiss, Jared
    CLINICS IN CHEST MEDICINE, 2020, 41 (02) : 237 - +